NCT01254578 2017-09-25
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
National Cancer Institute (NCI)
Phase 1 Completed
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)